| Chemical Properties | Back Directory | [density ]
1.38±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (470.77 mM; Need ultrasonic) | [form ]
Solid | [pka]
7.75±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1). | [storage]
Store at -20°C | [References]
[1] Martina Delbeck, et al. Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders. Patent WO2018228907A1. |
|
|